Natural killer (NK) cell function in paroxysmal nocturnal hemoglobinuria: A deficiency of NK cells, but not an NK cell deficiency

To the editor: Treatment of the glycosylphosphatidylinositol (GPI) anchor deficiency paroxysmal nocturnal hemoglobinuria (PNH) has been revolutionized by the use of the anti-C5 antibody eculizumab, which blocks complement-mediated hemolysis and the associated pathology.[1][1],[2][2] In addition to